S
Steven Piantadosi
Researcher at Johns Hopkins University
Publications - 9
Citations - 1330
Steven Piantadosi is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Factorial experiment & Ex vivo. The author has an hindex of 7, co-authored 9 publications receiving 1311 citations. Previous affiliations of Steven Piantadosi include Johns Hopkins University School of Medicine.
Papers
More filters
Journal Article
Bioactivity of Autologous Irradiated Renal Cell Carcinoma Vaccines Generated by ex Vivo Granulocyte-Macrophage Colony-stimulating Factor Gene Transfer
Jonathan W. Simons,Elizabeth M. Jaffee,Christine E. Weber,Hyam I. Levitsky,William G. Nelson,Michael A. Carducci,Audrey J. Lazenby,Lawrence K. Cohen,Christy C. Finn,Shirley M. Clift,Karen M. Hauda,Lisa A. Beck,Kristin M. Leiferman,Albert H. Owens,Steven Piantadosi,Glenn Dranoff,Richard C. Mulligan,Drew M. Pardoll,Fray F. Marshall +18 more
TL;DR: This Phase I study demonstrated the feasibility, safety, and bioactivity of an autologous GM-CSF gene-transduced tumor vaccine for RCC patients.
Journal Article
A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy.
Theodore L. DeWeese,H. G. Van Der Poel,Shiyong Li,Bahar Mikhak,R. Drew,Marti Goemann,Ulrike M. Hamper,Robert DeJong,N. Detorie,Ronald Rodriguez,T. Haulk,Angelo M. DeMarzo,Steven Piantadosi,De-Chao Yu,Yun-Ching Chen,D. R. Henderson,Michael A. Carducci,William G. Nelson,Jonathan W. Simons +18 more
TL;DR: This study documents that intraprostatic delivery of CV706 can be safely administered to patients, even at high doses, and the data suggest that CV706 possesses enough clinical activity, as reflected by changes in serum PSA, to warrant additional clinical and laboratory investigation.
Journal ArticleDOI
Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer
TL;DR: Widespread early detection programs for prostate cancer resulted in downward stage migration in men presenting with prostate cancer at the authors' institution during the last 18 years, and a biochemical recurrence-free survival advantage is demonstrated.
Journal ArticleDOI
Continuing controversy over adjuvant therapy of pancreatic cancer
Journal ArticleDOI
Toxicity, Efficacy, and Pharmacology of Suramin in Adults With Recurrent High-Grade Gliomas
Stuart A. Grossman,Surasak Phuphanich,G. J. Lesser,Jack M. Rozental,Louise B. Grochow,Joy D. Fisher,Steven Piantadosi +6 more
TL;DR: It is demonstrated that suramin is well tolerated by patients with recurrent high-grade gliomas and may have efficacy in this disease, and its pharmacology seems unaffected by anticonvulsants.